Kirn D - Search Results

Year	Number of Results
1993	2
1994	1
1995	4
1996	6
1997	1
1998	4
1999	4
2000	13
2001	9
2002	10
2003	6
2004	8
2005	10
2006	4
2007	10
2008	15
2009	5
2010	9
2011	9
2012	5
2013	6
2014	2
2015	16
2016	6
2017	5
2018	6
2019	9
2020	4
2021	4
2022	6
2023	3
2024	2

1

Trial of Solanezumab in Preclinical Alzheimer's Disease.

Sperling RA, Donohue MC, Raman R, Rafii MS, Johnson K, Masters CL, van Dyck CH, Iwatsubo T, Marshall GA, Yaari R, Mancini M, Holdridge KC, Case M, Sims JR, Aisen PS; A4 Study Team. Sperling RA, et al. N Engl J Med. 2023 Sep 21;389(12):1096-1107. doi: 10.1056/NEJMoa2305032. Epub 2023 Jul 17. N Engl J Med. 2023. PMID: 37458272 Free PMC article. Clinical Trial.

2

Effect of Structured, Moderate Exercise on Kidney Function Decline in Sedentary Older Adults: An Ancillary Analysis of the LIFE Study Randomized Clinical Trial.

Shlipak MG, Sheshadri A, Hsu FC, Chen SH, Jotwani V, Tranah G, Fielding RA, Liu CK, Ix J, Coca SG; LIFE Investigators. Shlipak MG, et al. JAMA Intern Med. 2022 Jun 1;182(6):650-659. doi: 10.1001/jamainternmed.2022.1449. JAMA Intern Med. 2022. PMID: 35499834 Free PMC article. Clinical Trial.

3

Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies.

Salabarria SM, Corti M, Coleman KE, Wichman MB, Berthy JA, D'Souza P, Tifft CJ, Herzog RW, Elder ME, Shoemaker LR, Leon-Astudillo C, Tavakkoli F, Kirn DH, Schwartz JD, Byrne BJ. Salabarria SM, et al. Among authors: kirn dh. J Clin Invest. 2024 Jan 2;134(1):e173510. doi: 10.1172/JCI173510. J Clin Invest. 2024. PMID: 37988172 Free PMC article.

4

Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer.

Kirn D. Kirn D. Oncogene. 2000 Dec 27;19(56):6660-9. doi: 10.1038/sj.onc.1204094. Oncogene. 2000. PMID: 11426652 Review.

5

Replication-selective adenoviruses as oncolytic agents.

Heise C, Kirn DH. Heise C, et al. Among authors: kirn dh. J Clin Invest. 2000 Apr;105(7):847-51. doi: 10.1172/JCI9762. J Clin Invest. 2000. PMID: 10749561 Free PMC article. Review. No abstract available.

6

Oncolytic biotherapy: a novel therapeutic plafform.

Hawkins LK, Lemoine NR, Kirn D. Hawkins LK, et al. Among authors: kirn d. Lancet Oncol. 2002 Jan;3(1):17-26. doi: 10.1016/s1470-2045(01)00618-0. Lancet Oncol. 2002. PMID: 11905600 Review.

7

Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic.

Breitbach CJ, Parato K, Burke J, Hwang TH, Bell JC, Kirn DH. Breitbach CJ, et al. Among authors: kirn dh. Curr Opin Virol. 2015 Aug;13:49-54. doi: 10.1016/j.coviro.2015.03.016. Epub 2015 Apr 17. Curr Opin Virol. 2015. PMID: 25900822 Review.

8

The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594).

Breitbach CJ, Bell JC, Hwang TH, Kirn DH, Burke J. Breitbach CJ, et al. Among authors: kirn dh. Oncolytic Virother. 2015 Jan 28;4:25-31. doi: 10.2147/OV.S59640. eCollection 2015. Oncolytic Virother. 2015. PMID: 27512667 Free PMC article. Review.

9

Genetic theraphy for cancer: hurdles remain.

Kirn D. Kirn D. Mol Ther. 2005 Apr;11(4):493. doi: 10.1016/j.ymthe.2005.02.008. Epub 2005 Mar 2. Mol Ther. 2005. PMID: 28182868 No abstract available.

10

Genetic therapy for cancer: hurdles remain.

Kirn D. Kirn D. Mol Ther. 2005 Apr;11(4):493. doi: 10.1016/j.ymthe.2005.02.008. Mol Ther. 2005. PMID: 15771952 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

185 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

185 results

Results by year